Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported revenue of $2.8 million for the nine months ended Sept. 30, 2026, a 167% increase from $1.05 million in the prior-year period, according to Scinai Immunotherapeutics (NASDAQ: SCNI). The growth reflects the expansion of its contract development and manufacturing organization (CDMO) operations, including the February acquisition of Recipharm Israel.
The company reported an operating loss of $6.56 million and a net loss of $390,000, with the latter benefiting from a $6.4 million noncash bargain purchase gain related to the acquisition. Scinai also reported approximately $8.32 million in committed customer orders as of Nov. 4, 2026, up more than 330% from year-end 2025. This includes an expanded U.S. customer agreement with approximately $5.1 million in committed base service fees.
These figures matter because they suggest Scinai's CDMO business is gaining commercial traction. The sharp rise in committed orders provides visibility into future revenue, while the Recipharm Israel acquisition appears to have immediately boosted the company's manufacturing capacity and customer base. The bargain purchase gain also flattered the net loss figure, though the operating loss of $6.56 million indicates the company is still investing heavily in growth.
Scinai generated approximately $5.3 million in net proceeds from October financing transactions, bringing reported bank balances to approximately $8.1 million as of Oct. 27. Based on current projections and anticipated customer payments, Scinai expects sufficient operating liquidity through late 2027, with potential additional clinical manufacturing work that could extend its runway into 2028. This liquidity outlook is important for investors because it reduces near-term financing risk and gives the company time to execute on its strategy.
The company operates a dual model: a CDMO services business and an immunology-focused therapeutic development platform. The CDMO side, through Scinai Biopharma Services Ltd., provides development and manufacturing services to biotechnology and pharmaceutical companies from facilities in Jerusalem and Yavne, Israel. The therapeutic pipeline includes candidates licensed from the Max Planck Society and PinCell S.r.l. The revenue growth and order backlog are primarily tied to the CDMO segment, which now appears to be the company's main near-term value driver.
For a fuller picture, the complete press release is available at https://ibn.fm/1OlnB. The latest news and updates relating to SCNI are available in the company's newsroom at https://ibn.fm/SCNI. The announcement was distributed through InvestorWire, a communications platform within the Dynamic Brand Portfolio at IBN that offers services such as editorial syndication to 5,000+ outlets and social media distribution. Investors should review the full disclaimers at https://www.InvestorWire.com/Disclaimer.
